Prediction of Patient's Response to OnabotulinumtoxinA Treatment for Migraine

Heliyon - Netherlands
doi 10.1016/j.heliyon.2018.e01043
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P010. OnabotulinumtoxinA for Treatment of Chronic Migraine: Results After 1 Year of Treatment

Journal of Headache and Pain
MedicineNeurologyAnesthesiologyPain Medicine
2015English

Prophylactic Treatment of Migraine; The Patient's View, a Qualitative Study

BMC Family Practice
Family Practice
2012English

OnabotulinumtoxinA Treatment for Chronic Migraine: Experience in 52 Patients Treated With the PREEMPT Paradigm

SpringerPlus
Multidisciplinary
2015English

OnabotulinumtoxinA for the Treatment of Overactive Bladder

Research and Reports in Urology
Urology
2014English

Patient's Response to the Research

BMJ
2003English

Lasmiditan for the Acute Treatment of Migraine: Subgroup Analyses by Prior Response to Triptans

Cephalalgia
MedicineNeurology
2019English

Real-World Effectiveness of onabotulinumtoxinA Treatment for the Prevention of Headaches in Adults With Chronic Migraine in Australia: A Retrospective Study

Journal of Headache and Pain
MedicineNeurologyAnesthesiologyPain Medicine
2019English

P025. Two-Year Follow-Up With OnabotulinumtoxinA for Chronic Migraine: A Real Life Evaluation of 113 Patients

Journal of Headache and Pain
MedicineNeurologyAnesthesiologyPain Medicine
2015English

A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy